EUVIMEDEUVIMED entdecken
Crossref

Neoadjuvant Therapy and Pancreatic Cancer Resection Outcomes: A Retrospective Analysis at a Quaternary Care Center

Youssef E Dib, Ashton A Connor, Jason Todd, Khush A Patel, Ahmed Elaileh, Eamonn Mm Quigley, Caroline J Simon, Yee Lee Cheah, Constance M Mobley, Kelvin Allenson, Nestor Esnaola, Wade R Rosenberg und 8 weitere

Journal of Surgical Research · 2026-05 · 321 · 84-95

DOI: 10.1016/j.jss.2026.02.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Research, 2026-05. Verfasst von Youssef E Dib und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Houston Methodist Hospital, Houston, Texas. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neoadjuvant Therapy, Adenocarcinoma, Pancreatectomy. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Pancreatic adenocarcinoma (PA) has a rising incidence and high mortality, with current overall 5-y survival being less than 15%. Whether outcomes may be improved by the use of neoadjuvant therapy prior to resection is not fully established. MATERIALS AND METHODS Data from patients who underwent resection of PA between 2015 and 2024 at a single United States center were retrospectively reviewed. Patient records were stratified by receipt of neoadjuvant therapy (NAT). Outcomes were postresection overall survival, recurrence-free survival, and pathological features at resection. RESULTS Between 2015 and 2024, 313 patients underwent resection for PA, of whom 62 (19.8%) received NAT and 229 (73.2%) underwent upfront resection (UFR); 22 (7.0%) patients were excluded due to missing data. Of the 62 NAT patients, three (4.9%) demonstrated complete response on pathological examination, 44 (72%) demonstrated incomplete response, 12 (20%) demonstrated no response, and two had no report (3.1%). The NAT cohort exhibited significantly lower preoperative CA19-9 levels (P < 0.001) and lower T and N stages (P = 0.006 and P < 0.001, respectively), along with reduced rates of perineural and lymphovascular invasion (both P < 0.001). Complete tumor removal with negative margins (R0) was similar between both groups, 49 (79%) in the NAT group versus 169 (74%) in the UFR group (P = 0.4). Neither overall survival nor recurrence-free survival significantly differed between the NAT and UFR groups (hazard ratio= 1.17, 95% confidence interval: 0.76-1.78; hazard ratio= 0.93, 95% confidence intervals: 0.60-1.42, respectively). CONCLUSIONS In patients undergoing resection for pancreatic cancer, NAT was associated with less advanced pathologic features at resection, but these did not translate into improved postresection outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsNeoadjuvant TherapyAdenocarcinomaPancreatectomyNeoplasm Recurrence, LocalHumansRetrospective StudiesFemaleMaleMiddle AgedAgedTreatment OutcomePancreasMargins of ExcisionPathologic Complete ResponseChemotherapy, AdjuvantAdult

Stichwörter der Autor:innen

ChemotherapyNeoadjuvant chemotherapyOverall survivalPancreatic adenocarcinomaPancreatic surgeryRecurrence-free survival

Autor:innen und Institutionen

  • Department of Surgery, Houston Methodist Hospital, Houston, Texas.
  • Department of Surgery, Houston Methodist Hospital, Houston, Texas. Electronic address: aogaber@houstonmethodist.org.

Zitieren

APA

Dib, Y. E., Connor, A. A., Todd, J., Patel, K. A., Elaileh, A., Quigley, E. M., Simon, C. J., Cheah, Y. L., Mobley, C. M., Allenson, K., Esnaola, N., Rosenberg, W. R., Abdelrahim, M., Heyne, K. E., Dhingra, S., Schwartz, M. R., Moore, L. W., Ghobrial, R. M., Saharia, A., & Gaber, A. O. (2026). Neoadjuvant Therapy and Pancreatic Cancer Resection Outcomes: A Retrospective Analysis at a Quaternary Care Center. Journal of Surgical Research, 321, 84-95. https://doi.org/10.1016/j.jss.2026.02.012

Vancouver

Dib YE, Connor AA, Todd J, Patel KA, Elaileh A, Quigley EM, et al. Neoadjuvant Therapy and Pancreatic Cancer Resection Outcomes: A Retrospective Analysis at a Quaternary Care Center. Journal of Surgical Research. 2026;321:84-95. doi:10.1016/j.jss.2026.02.012

BibTeX
@article{Dib2026,
  author = {Dib, Youssef E and Connor, Ashton A and Todd, Jason and Patel, Khush A and Elaileh, Ahmed and Quigley, Eamonn Mm and Simon, Caroline J and Cheah, Yee Lee and Mobley, Constance M and Allenson, Kelvin and Esnaola, Nestor and Rosenberg, Wade R and Abdelrahim, Maen and Heyne, Kirk E and Dhingra, Sadhna and Schwartz, Mary R and Moore, Linda W and Ghobrial, R Mark and Saharia, Ashish and Gaber, A Osama},
  title = {Neoadjuvant Therapy and Pancreatic Cancer Resection Outcomes: A Retrospective Analysis at a Quaternary Care Center},
  journal = {Journal of Surgical Research},
  year = {2026},
  volume = {321},
  pages = {84--95},
  doi = {10.1016/j.jss.2026.02.012}
}
Kostenlos starten →